FDA Clarifies Which Digital Wellness Tools Fall Under Medical Device Regulation

The FDA has spelled out more details on its oversight of digital health products. Its risk-based framework looks at how a tool is meant to be used instead of what it runs on. Many apps built for basic wellness tracking do not meet the definition of a medical device under this view. The agency brings its thinking together in the Digital Health Center of Excellence and in two guidance documents updated in 2022 and 2023.

The agency points to its Digital Health Center of Excellence as the central spot for its thinking on these issues. That hub describes the updated oversight approach and links to all related guidance. [1]

The FDA maintains a risk-based approach to digital health oversight. [1] It focuses on intended use rather than platform. Many wellness apps fall outside the device definition as a result.

The Clinical Decision Support Software guidance came out on September 22, 2022. [2] That document sets four key criteria. Software that meets all four does not count as a device.

One update to the policy for device software functions and mobile medical applications landed on June 1, 2023. [3] It lists cases where the FDA will not enforce compliance. Mobile apps for general health tracking sit in that category.

The framework also touches on AI and machine learning tools. It accounts for systems that learn and change over time. Developers can find notes on regulatory pathways, cybersecurity and real-world evidence in the same collection of resources. [1]

What this means

The clarifications separate simple tracking tools from those that diagnose or treat. Low-risk wellness products generally face lighter oversight. Products linked to clinical decisions may still require formal review and evidence of safety. The approach also flags cybersecurity and performance monitoring as important elements for tools that do fall under regulation.

Key takeaways

• The FDA maintains a risk-based approach to digital health oversight that focuses on intended use rather than platform. [1]
• Clinical decision support software is not regulated as a device when it meets four specified criteria. [2]
• The 2023 policy update identifies mobile apps for general health tracking as an area of enforcement discretion. [3]
• Oversight centers on patient safety rather than the technology itself. [1]
• Cybersecurity and real-world performance monitoring appear as considerations for regulated digital health products. [1]

Limitations

FDA guidance documents are not legally binding. Rapid evolution of AI and ML capabilities may require frequent updates. The materials do not address international harmonization in detail. They focus primarily on software rather than hardware-integrated digital health systems.